Melasma Treatment: Why Wavelength and Strategy Matter

Melasma requires more than pigment removal

Melasma is not a simple brown spot.

That distinction should change the way a clinic evaluates both treatment strategy and laser technology.

Melasma is chronic and recurrence-prone. It is influenced by melanocyte activity, ultraviolet and visible-light exposure, hormones, inflammation, dermal changes, and — in a meaningful subset of patients — altered vascularity. Treating it as though it were an isolated lentigo can miss the biology that makes the condition difficult in the first place.

The better question is not simply “Can this laser hit pigment?”

It is:

Which wavelength gives the provider the most logical optical starting point for pigment-prone skin — and what treatment architecture is available after that?

1064 nm first. Because wavelength matters.

For melasma, wavelength is not a footnote on a specification sheet.

Epidermal melanin is a competing chromophore. As baseline epidermal pigmentation increases, the importance of limiting unnecessary interaction with that melanin increases as well.

1064 nm Nd:YAG has lower relative absorption by epidermal melanin than 755 nm alexandrite and penetrates more deeply. That gives 1064 nm a more favorable wavelength profile when epidermal melanin sparing is a priority — particularly in pigment-prone and melanin-rich skin.

This does not mean that every 755 nm treatment is inappropriate or that wavelength alone determines safety. It does mean that 755 nm and 1064 nm should not be treated as interchangeable simply because both can be delivered in the picosecond domain.

The clinical evidence reflects that difference

A 2023 systematic review and meta-analysis of six randomized controlled trials evaluated picosecond treatment at 1064, 755, 595, and 532 nm. In wavelength subgroup analysis, 1064 nm picosecond treatment significantly reduced MASI/mMASI with no significant side effects reported in that subgroup, while the 755 nm subgroup did not significantly outperform topical depigmenting agents and reported post-inflammatory hyperpigmentation. View the PubMed record.

A separate 2023 randomized, controlled, assessor-blinded trial compared non-fractional 1064 nm picosecond Nd:YAG, 755 nm picosecond alexandrite, and 2% hydroquinone in 60 patients with Fitzpatrick III–IV skin. The 1064 nm group produced the greatest MASI reduction; the 755 nm group performed comparably to hydroquinone. View the published trial.

That is an important buying lesson:

“Picosecond” is not the whole technology story. Wavelength still matters.

Melasma is more than an epidermal pigment problem

A landmark histologic study of 50 women with melasma found significantly increased number and size of dermal blood vessels in melasma lesions, along with increased VEGF expression. The authors concluded that increased vascularity is a major finding in melasma. View the PubMed record.

That does not mean every melasma patient needs vascular laser treatment. It does mean that a modern melasma discussion should move beyond the idea that the condition is simply excess superficial melanin waiting to be blasted away.

For a clinic evaluating technology, this raises a more sophisticated question:

Can the platform give the provider more than one treatment behavior at 1064 nm?

Why multi-mode 1064 nm is commercially and clinically interesting

A 2025 randomized evaluator-blinded trial compared a 755 nm picosecond alexandrite protocol with a combined Q-switched plus long-pulse 1064 nm Nd:YAG strategy in 40 patients with Fitzpatrick III–IV skin.

Both groups improved, but the combined 1064 nm group achieved significantly greater overall MASI improvement. Pain scores were significantly higher in the 755 nm group, while overall safety profiles were similar. View the PubMed record.

The study did not enroll Fitzpatrick V–VI, so it should not be presented as direct evidence for those phototypes. It also does not prove that the long-pulse component worked specifically by treating vascularity. But it does reinforce a valuable principle:

Melasma treatment performance cannot be reduced to pulse duration alone. Wavelength and treatment architecture matter.

Pro 1 Pico: more than a single melasma setting

The Pro 1 Pico is built around 1064 nm as its primary wavelength and extends that wavelength across multiple treatment behaviors.

For melasma-focused treatment planning, that means the provider is not limited to one generic “pico” interaction:

• 500 ps 1064 nm picosecond delivery for photoacoustic pigment-focused treatment.
• PTP dual-pulse delivery for an additional picosecond energy-delivery option.
• Long-pulse 1064 nm Nd:YAG as a separate photothermal pathway when vascular findings or other appropriate 1064 nm targets are part of the treatment plan.
• A broader platform that also supports pigment, tattoo and PMU correction, vascular treatments, skin quality, and fractional remodeling — so melasma does not have to carry the economics of the device by itself.

That last point matters in the real world. A clinic is not buying a wavelength for one patient. It is buying a platform that needs to stay productive throughout the week.

Melasma may bring the patient in. The platform should give the practice more to offer.

Patients seeking melasma treatment frequently belong to the same broader aesthetic population seeking help with uneven pigment, sun damage, redness, visible vessels, pores, texture, post-acne changes, and ongoing skin quality.

A platform built around multiple treatment categories gives the practice a way to move beyond a single melasma appointment and build a broader treatment relationship.

With Pro 1 Pico, that treatment menu can extend into:

Pigmentation. PMU correction. Tattoo removal. Vascular and redness treatments. PulseStack™ 750 skin-quality programs. PicoMatrix™ scar and texture remodeling. Hair restoration. Selected hair reduction.

That is a stronger device-utilization story than buying a system around one indication alone.

Treat improvement. Plan for management.

Melasma remains recurrence-prone regardless of device marketing.

The goal is not to promise a permanent cure. The goal is to choose a wavelength and treatment strategy that make biological sense, manage cumulative treatment exposure intelligently, support photoprotection and maintenance, and give the provider enough flexibility to respond to the patient rather than forcing every case into one setting.

Melasma is a managed condition — and the technology should be sophisticated enough to manage it that way.

Continue the melasma evidence series

• Why Melasma Requires a Conservative Energy Strategy
• Pro 1 Pico for Melasma
• The Vascular Component of Melasma
• Why Melasma Requires a Conservative Energy Strategy

Treatment selection, parameters, and candidacy remain provider-directed. Results vary and melasma may recur.